FDA Approves CLOZAPINE — Mylan Pharmaceuticals Inc.

Mylan Pharmaceuticals Inc. received FDA approval on May 27, 1999, for its generic version of oral clozapine (Clozaril), marking an important step towards expanding access to this critical treatment for severe, treatment-resistant schizophrenia. The addition of a generic entry to the market is expected to significantly broaden patient access and reduce costs for healthcare providers and payers managing long-term care for this indigence population.